OR WAIT null SECS
PharmaZell (Raubling, Germany) and Novasep (Lyon, France) have announced the completion of their merger, following exclusive negotiations initiated in September 2021. This strategic merger creates a technology driven, leading contract development and manufacturing (CDMO) and active pharmaceutical ingredient (API) manufacturer.
“Today is a very important step on our journey to better support our customers and the patients they serve. This merger is a significant opportunity to further improve our offering, providing a broader set of technologies, a global manufacturing footprint, and an end-to-end life cycle management,” said Sylke Hassel, former CEO of PharmaZell and CEO of the new group.
The companies believe their combined assets, capabilities, experience, and expertise are highly complementary, and they intend to create a global company offering CDMO and API manufacturing across Europe, the United States, and India. “I am delighted to be joining the Board of Directors where I will contribute to the strategic direction of the new company. I have great confidence that the group will become a major player thanks to the complementarity of its offer and the combination of talents. I would like to express my deepest gratitude to all Novasep’s employees for their commitment and hard work during these past years and remain confident that they will continue to strongly contribute to the development of the new group,” said Michel Spagnol, former CEO of Novasep and future member of the board of directors.